1130 related articles for article (PubMed ID: 11156256)
21. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
22. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
Mohammad RM; Diwakaran H; Maki A; Emara MA; Pettit GR; Redman B; al-Katib A
Leuk Res; 1995 Sep; 19(9):667-73. PubMed ID: 7564478
[TBL] [Abstract][Full Text] [Related]
23. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
[TBL] [Abstract][Full Text] [Related]
24. Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
Ohnoshi T; Hayashi K; Ueno K; Tada A; Mizuta J; Tagawa S; Matsutomo S; Saito S; Kawashima K; Yoshino T
Int J Hematol; 1993 Aug; 58(1-2):93-8. PubMed ID: 7693030
[TBL] [Abstract][Full Text] [Related]
25. Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome.
Vaisheva F; Delbes G; Hales BF; Robaire B
J Androl; 2007; 28(4):578-87. PubMed ID: 17409468
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
27. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
28. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
30. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
31. [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
Sampi K; Honda T; Hattori M; Takayama S
Gan To Kagaku Ryoho; 1983 May; 10(5):1266-71. PubMed ID: 6191677
[TBL] [Abstract][Full Text] [Related]
32. New treatment strategies for aggressive lymphoma.
Younes A
Semin Oncol; 2004 Dec; 31(6 Suppl 15):10-3. PubMed ID: 15726533
[TBL] [Abstract][Full Text] [Related]
33. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
[TBL] [Abstract][Full Text] [Related]
34. The effect of biweekly CHOP and standard CHOP in different subgroups of diffuse large B-cell lymphoma.
Zhang Q; Wang J; Yu Z; Zhuang Y; Ma W; Jin S; Zhao S
Onkologie; 2009 Dec; 32(12):719-23. PubMed ID: 20016232
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
[TBL] [Abstract][Full Text] [Related]
36. CD5+ T-cell/histiocyte-rich large B-cell lymphoma.
Chang CC; Bunyi-Teopengco E; Eshoa C; Chitambar CR; Kampalath B
Mod Pathol; 2002 Oct; 15(10):1051-7. PubMed ID: 12379751
[TBL] [Abstract][Full Text] [Related]
37. [Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Sugimoto T; Matano S; Nishijima H; Kakuta K; Inamura K; Okamura T; Munemoto S; Satoh S
Gan To Kagaku Ryoho; 2007 Jan; 34(1):125-8. PubMed ID: 17220687
[TBL] [Abstract][Full Text] [Related]
38. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
39. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M
Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
